Renin–Angiotensin System Inhibition, Worsening Renal Function, and Outcome in Heart Failure Patients With Reduced and Preserved Ejection Fraction: A Meta-Analysis of Published Study Data
暂无分享,去创建一个
J. McMurray | A. Voors | P. Rossignol | J. M. ter Maaten | P. van der Meer | K. Damman | I. Beldhuis | Koen W Streng | J. T. ter Maaten
[1] S. Solomon,et al. Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM‐study programme , 2016, European journal of heart failure.
[2] P. Ponikowski,et al. [2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure]. , 2016, Kardiologia polska.
[3] Volkmar Falk,et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure , 2016, Revista espanola de cardiologia.
[4] W. Paulus,et al. Connecting heart failure with preserved ejection fraction and renal dysfunction: the role of endothelial dysfunction and inflammation , 2016, European journal of heart failure.
[5] K. Damman,et al. The kidney in heart failure: an update. , 2015, European heart journal.
[6] J. McMurray,et al. Terminology and definition of changes renal function in heart failure. , 2014, European heart journal.
[7] R. McKelvie,et al. Worsening renal function and outcome in heart failure patients with preserved ejection fraction and the impact of angiotensin receptor blocker treatment. , 2014, Journal of the American College of Cardiology.
[8] Sanjiv J Shah,et al. Spironolactone for heart failure with preserved ejection fraction. , 2014, The New England journal of medicine.
[9] C. O'connor,et al. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. , 2014, European heart journal.
[10] H. Krum,et al. Worsening renal function during renin–angiotensin–aldosterone system inhibitor initiation and long‐term outcomes in patients with left ventricular systolic dysfunction , 2014, European journal of heart failure.
[11] J. Cohn,et al. Interaction between baseline and early worsening of renal function and efficacy of renin–angiotensin–aldosterone system blockade in patients with heart failure: insights from the Val‐HeFT study , 2013, European journal of heart failure.
[12] P. Ponikowski,et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial , 2013, European heart journal.
[13] R. Wachter,et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. , 2013, JAMA.
[14] Akshay S. Desai,et al. Influence of baseline and worsening renal function on efficacy of spironolactone in patients With severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study). , 2012, Journal of the American College of Cardiology.
[15] B. Pitt,et al. Determinants and Consequences of Renal Function Variations With Aldosterone Blocker Therapy in Heart Failure Patients After Myocardial Infarction: Insights From the Eplerenone Post–Acute Myocardial Infarction Heart Failure Efficacy and Survival Study , 2012, Circulation.
[16] S. Kimmel,et al. Prognostic Importance of Early Worsening Renal Function After Initiation of Angiotensin-Converting Enzyme Inhibitor Therapy in Patients With Cardiac Dysfunction , 2011, Circulation. Heart failure.
[17] J. Sterne,et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials , 2011, BMJ : British Medical Journal.
[18] Akshay S. Desai,et al. Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction. , 2011, European heart journal.
[19] C. Bias. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials , 2011 .
[20] S. Solomon,et al. Effects of the Oral Direct Renin Inhibitor Aliskiren in Patients With Symptomatic Heart Failure , 2008, Circulation. Heart failure.
[21] N. Freemantle,et al. FASTTRACK : The perindopril in elderly people with chronic heart failure (PEP-CHF) study , 2006 .
[22] S. Solomon,et al. Increase in creatinine and cardiovascular risk in patients with systolic dysfunction after myocardial infarction. , 2006, Journal of the American Society of Nephrology : JASN.
[23] N. Freemantle,et al. Perindopril for elderly people with chronic heart failure: the PEP‐CHF study , 1999, European heart journal.
[24] M. Lye,et al. The Effect of Quinapril on Functional Status of Elderly Patients with Diastolic Heart Failure , 2003, Cardiovascular Drugs and Therapy.
[25] M. Pfeffer,et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme , 2003, The Lancet.
[26] D. Grobbee,et al. Accelerated decline and prognostic impact of renal function after myocardial infarction and the benefits of ACE inhibition: the CATS randomized trial. , 2003, European heart journal.
[27] Douglas G Altman,et al. Interaction revisited: the difference between two estimates , 2003, BMJ : British Medical Journal.
[28] M. Pfeffer,et al. Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors. , 2000, American heart journal.
[29] E. Aliot,et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. , 1995, The New England journal of medicine.
[30] G. Murray,et al. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators , 1993 .
[31] K. Swedberg,et al. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1988, The American journal of cardiology.
[32] J. Cohn,et al. Hemodynamic and clinical response to enalapril, a long-acting converting-enzyme inhibitor, in patients with congestive heart failure. , 1984, Circulation.